alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
"['G776V', 'L841V', 'T798M', 'D821N', 'L755W', 'V842I', 'A710V', 'V697L', 'L755A', 'G776S', 'L869R', 'E717D', 'L866M', 'G815R', 'Q709L', 'V794M', 'D808N', 'Exon 20 in-frame insertions', 'V777M', 'L768S', 'V773L', 'L726F', 'L726I', 'T733I', 'L755P', 'L755S', 'I767M', 'D769H', 'D769Y', 'V777L']","[{'ncitCode': 'C199022', 'drugName': 'Zongertinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['40293180'],[],"Zongertinib is an orally available, HER2-selective tyrosine kinase inhibitor that is FDA-approved for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. ERBB2 tyrosine kinase domain mutations are defined as activating single-nucleotide variants in exons 18 through 21 within the tyrosine kinase domain and exon 20 insertion mutations and are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I Beamion LUNG-1 (NCT04886804) trial of zongertinib in patients with previously treated ERBB2-mutant NSCLC.

In this trial, patients with previously treated NSCLC with an ERBB2 mutation in the TKD (n=75 [ERBB2 mutations include: A775_G776insYVMA (43), P780_Y781insGSP (8), A775_G776insYVMA+other (5), G776>VC (3), L755P (2), G776V (2), other (12)]) demonstrated an overall response rate (ORR) of 71% (95% CI=60-80), with a 7% (n=5) complete response (CR) rate and 64% (n=48) partial response (PR) rate, and a disease control rate (DCR) of 96% (95% CI=89-99) (PMID: 40293180). Of patients who were previously treated with a HER2-directed antibody drug conjugate (ADC) (n=31 [ERBB2 mutations include: A775_G776insYVMA (18), P780_Y781insGSP (3), G776>VC (3), other (7)]), the ORR was 48% (95% CI=32-65), with a 3% (n=1) CR rate and 45% (n=14) PR rate, and the DCR was 97% (95% CI=84-99) (PMID: 40293180). Patients with previously treated NSCLC with an ERBB2 mutation not in the tyrosine kinase domain (n=20 [ERBB2 mutations include: S310F (6), V659E (6), S310Y (4), P1199S (1), D277Y (1), S113F (1), G660D (1)]) demonstrated an ORR of 30% (95% CI=15-52), with a 30% (n=5 [S310F (3), V659E (3)]) PR rate, and a DCR of 65% (95% CI=43-82) (PMID: 40293180)."
['Oncogenic Mutations'],"[{'ncitCode': 'C128799', 'drugName': 'Trastuzumab Deruxtecan'}]",[],LEVEL_1,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['34534430'],[],"Trastuzumab Deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate that is FDA-approved for patients with HER2-mutant non-small cell lung cancer (NSCLC). FDA approval was based on the data from the Phase II dose optimization DESTINY-Lung02 study of trastuzumab deruxtecan in 52 patients with HER2-mutant NSCLC in which the confirmed overall response rate was 57.7% (95% CI= 43.2-71.3), with one of 54 patients having a complete response, 29 of 54 patients having a partial response, and with a median duration of response of 8.7 months (95% CI= 7.1-NE). FDA approval was supported by the Phase II DESTINY-Lung01 trial of trastuzumab deruxtecan in 91 patients with HER2-mutant NSCLC in which the overall response rate was 55% (95% CI=44-65), the median duration of response was 9.3 months (95% CI=5.7-14.7), the median progression-free survival was 8.2 months (95% CI=6.0-11.9), and the median overall survival was 17.8 months (95% CI=13.8-22.1) (PMID: 34534430)."
['Oncogenic Mutations'],"[{'ncitCode': 'C82492', 'drugName': 'Ado-Trastuzumab Emtansine'}]",[],LEVEL_2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['31588020', '29989854', '30206164']",[],"Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in which an ERBB2-directed monoclonal antibody is conjugated to DM1, a microtubule-inhibitory agent. The NCCN lists ado-trastuzumab emtansine as another recommended therapy for patients with NSCLC harboring ERBB2 mutations. In the lung cancer cohort of a Phase II basket trial of T-DM1 in patients with ERBB2-mutant solid tumors, 44% (95% CI=22%-69%) of eighteen patients had a partial response, with a median progression-free survival of five months (95% CI=3-9) (PMID: 29989854). Of the eight patients who had a partial response, four had been treated with prior anti-HER2 therapy, and all eight had one of the following ERBB2 mutations: A775_G776insYVMA, G778_P780dup, G776_V777insVCV, V659E or S310F (PMID: 29989854). Responses to T-DM1 have also been seen in patients with ERBB2-amplified non-small cell lung cancer (NSCLC) (PMID: 30206164). The addition of poziotinib may enhance the response of patients with NSCLC to T-DM1 (PMID: 31588020)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 878, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Cervical Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Cervix', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38211393'],[],"Neratinib is an orally available, small-molecule pan-HER targeted inhibitor that is FDA-approved as a single agent for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The NCCN Cervical Cancer Guidelines (V1.2025) lists neratinib under ""Recurrent or Metastatic Disease - Second-line or Subsequent Therapy - Useful in Certain Circumstances"" for patients with ERBB2 mutant cervical cancer. NCCN recommendation was based on the results of the Phase II SUMMIT (NCT01953926) trial of neratinib in 22 patients with ERBB2 mutant cervical cancer (n=10, S310F/Y; n=2, S310F/Y + V842I; n=2, R678Q; n=1: S310F + G660D, V697L, D769H, T733I + R678Q, G776V, E695D, G832E, D769N) (PMID: 38211393).

In the Phase II SUMMIT (NCT01953926) trial, the ERBB2 mutant cervical cohort demonstrated an overall response rate (ORR) of 18.2% (n=4) (95% CI=5.2-40.3), with a 4.5% (n=1 [S310F]) complete response rate, 13.6% (n=3 [S310F (2), S310F + V842I]) partial response rate and 27.3% (n=6 [S310F, S310F + G660D, D769H/N, V697L, R678Q]) stable disease rate, a median progression-free survival (PFS) of 5.1 months (95% CI=1.7-7.2) and a median duration of response (DOR) of 7.6 months (95% CI=5.6-12.3) (PMID: 38211393)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}, {'ncitCode': 'C1647', 'drugName': 'Trastuzumab'}, {'ncitCode': 'C1379', 'drugName': 'Fulvestrant'}]",[],LEVEL_2,LEVEL_Fda3,"{'id': 873, 'code': '', 'color': 'HotPink', 'name': '', 'mainType': {'id': None, 'name': 'Breast Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Breast', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37597578'],[],"Neratinib is an orally available, small-molecule pan-HER targeted inhibitor that is FDA-approved as a single agent for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The NCCN Breast Cancer Guidelines (V3.2025) lists neratinib under ""Emerging Biomarkers And Novel Therapies For Patients With Stage IV (M1) Disease"" for patients with HER2 activating mutations. NCCN recommendation was based on the results of the Phase I SUMMIT (NCT05372614) basket study of neratinib plus trastuzumab and fulvestrant in patients with HR+/HER2-negative metastatic breast cancer with activating HER2 mutation(s) and prior CDK4/6i therapy.
In the Phase I SUMMIT (NCT05372614) trial, patients with HER2 mutant breast cancer (n=48) demonstrated an overall response rate (ORR) of 42% (n=20), with one patient (n=1, multiple ERBB2 mutations) achieving complete response (CR) and 21 patients (n=4, L755S; n=5, exon 20 insertion; n=3, other kinase domain missense; n=5, V777L; n=1, S310F; n=3, multiple ERBB2 mutations) achieving partial response (PR), and a median progression-free survival (PFS) of 10.2 months (95% CI=6.1-18.6) (PMID: 37597578)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 873, 'code': '', 'color': 'HotPink', 'name': '', 'mainType': {'id': None, 'name': 'Breast Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Breast', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['17311002', '23220880', '29420467']",[],"Neratinib is a small molecule inhibitor of the ERBB2 and EGFR kinases that is FDA-approved for HER2-positive breast cancer previously treated with adjuvant trastuzumab and is a category 2B NCCN recommendation for patients with HER2-mutant breast cancer. In a Phase II basket trial of patients across multiple tumor types with ERBB2 activating mutations, the overall response rate at eight weeks in patients with HER2 non-amplified breast cancer (N=25) was 32% [95% CI= 15-54%]. ERBB2 mutations associated with a response in breast cancer included the HER2 hotspot extracellular domain mutation S310, HER2 kinase domain hotspot mutations, exon 20 insertions, and the non-hotspot complex insertion/substitution L755_E757delinsS. Responses were observed in patients with estrogen receptor (ER)+ (30%, 6/20) and ER- (40%, 2/5) tumors (PMID: 29420467). In vitro studies of cells engineered to express ERBB2 activating mutations have demonstrated that these mutations are sensitive to neratinib as measured by a decrease in colony formation in soft agar and a decrease in tumor volume in xenograft models (PMID: 23220880, 17311002)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23220880', '29420467']",[],"Neratinib is a small molecule inhibitor of the ERBB2 and EGFR kinases that is FDA-approved for HER2-positive breast cancer previously treated with adjuvant trastuzumab. In a Phase II basket trial of patients across multiple tumor types with ERBB2 activating mutations, clinical benefit was observed in patients with non-small cell lung cancer harboring ERBB2 S310, L755, V777, P780_Y781insGSP, and A775_G776insYVMA mutations (PMID: 29420467). In vitro studies of cells engineered to express ERBB2 activating mutations have demonstrated that these mutations are sensitive to neratinib as measured by a decrease in colony formation in soft agar and a decrease in tumor volume in xenograft models (PMID: 23220880)."
['Oncogenic Mutations'],"[{'ncitCode': 'C199022', 'drugName': 'Zongertinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['40293180'],[],"Zongertinib is an orally available, HER2-selective tyrosine kinase inhibitor. There are promising clinical data that support the use of zongertinib in patients with previously treated ERBB2-mutant non-small cell lung cancer (NSCLC). 
In the Phase I Beamion LUNG-1 (NCT04886804) trial of zongertinib in patients with previously treated ERBB2-mutant NSCLC, patients with previously treated NSCLC with an ERBB2 mutation in the tyrosine kinase domain (n=75 [ERBB2 mutations include: A775_G776insYVMA (43), P780_Y781insGSP (8), A775_G776insYVMA+other (5), G776>VC (3), L755P (2), G776V (2), other (12)]) demonstrated an overall response rate (ORR) of 71% (95% CI=60-80), with a 7% (n=5) complete response (CR) rate and 64% (n=48) partial response (PR) rate, and a disease control rate (DCR) of 96% (95% CI=89-99) (PMID: 40293180). Of patients who were previously treated with a HER2-directed antibody drug conjugate (ADC) (n=31 [ERBB2 mutations include: A775_G776insYVMA (18), P780_Y781insGSP (3), G776>VC (3), other (7)]), the ORR was 48% (95% CI=32-65), with a 3% (n=1) CR rate and 45% (n=14) PR rate, and the DCR was 97% (95% CI=84-99) (PMID: 40293180). Patients with previously treated NSCLC with an ERBB2 mutation not in the tyrosine kinase domain (n=20 [ERBB2 mutations include: S310F (6), V659E (6), S310Y (4), P1199S (1), D277Y (1), S113F (1), G660D (1)]) demonstrated an ORR of 30% (95% CI=15-52), with a 30% (n=5 [S310F (3), V659E (3)]) PR rate, and a DCR of 65% (95% CI=43-82) (PMID: 40293180)."
['Oncogenic Mutations'],"[{'ncitCode': 'C185187', 'drugName': 'Sevabertinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8504', 'abstract': 'Loong, HH. et al., ASCO 2025.'}]","Sevabertinib is an orally available, reversible dual EGFR/HER2-selective tyrosine kinase inhibitor. There are promising clinical data that support the use of sevabertinib in patients with ERBB2-mutant non-small cell lung cancer (NSCLC). 
In the Phase 1/2 SOHO-01 trial (NCT05099172) trial, patients with HER2-targeted therapy naïve NSCLC harboring an ERBB2 mutation (n=81 [ERBB2 mutations include: tyrosine kinase domain (TKD) mutations (72), non-TKD mutations (8), N/A (1)]) demonstrated an overall response rate (ORR) of 59.3% (95% CI=47.8-70.1), with a 1.2% (n=1) complete response (CR) rate, 58.0% (n=47) partial response (PR) rate and 27.2% (n=22) stable disease (SD) rate, and a disease control rate (DCR) of 84.0% (95% CI=74.1-91.2) (Abstract: Loong, HH. et al., ASCO 2025. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8504). Patients with systemic therapy naïve NSCLC harboring an ERBB2 mutation (n=39 [ERBB2 mutations include: TKD mutations (38), non-TKD mutations (1)]) demonstrated an ORR of 59.0% (95% CI=42.1-74.4), with a 59.0% (n=23) PR rate and 30.8% (n=12) SD rate, and a DCR of 84.6% (95% CI=69.5-94.1) (Abstract: Loong, HH. et al., ASCO 2025. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8504)."
['Oncogenic Mutations'],"[{'ncitCode': 'C1647', 'drugName': 'Trastuzumab'}, {'ncitCode': 'C38692', 'drugName': 'Pertuzumab'}, {'ncitCode': 'C1526', 'drugName': 'Docetaxel'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['15059883', '19934333', '28959366', '35073148']",[],"Trastuzumab and pertuzumab are both monoclonal antibodies against ERBB2/HER2 and docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. The triple combination of these therapeutic agents is FDA-approved for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. In a multicenter, nonrandomized phase II study (FCT 1703-R2D2, NCT03845270) of trastuzumab, pertuzumab and docetaxel in 45 patients with ERBB2-mutated, advanced non-small cell lung cancer who progressed after at least one platinum-based treatment, the objective response rate was 29% (n = 13/45) in which 58% of patients had stable disease (n = 26/45) and the median progression-free survival was 6.8 months (95% CI=4.0 to 8.5) (PMID: 35073148). Preclinical studies in HER2-overexpressing breast cancer cell lines and HER2-positive breast and non–small cell lung cancer xenograft models have shown that combining trastuzumab and pertuzumab resulted in greater antitumor activity compared to treatment with either antibody alone due to more comprehensive signaling blockade provided by the antibodies binding to different HER2 epitopes (PMID: 15059883, 19934333). In a separate preclinical study, treatment of a HER2-positive mouse xenograft model of breast cancer with trastuzumab, pertuzumab, and docetaxel resulted in enhanced apoptosis, infiltration of mononuclear cells, a strong reduction in the phosphorylation of HER2, EGFR, HER3, ERK, and AKT, as well as a slower tumor growth rate compared to controls (PMID: 28959366)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 897, 'code': '', 'color': 'MIXED', 'name': '', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'MIXED', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['36746967'],[],"Neratinib is an orally available, small-molecule pan-HER inhibitor that is FDA-approved as an extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. There are anecdotal clinical data to support the use of neratinib in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II SUMMIT (NCT01953926) trial of neratinib in patients with ERBB2 mutant solid tumors, patients with gallbladder cancer (n=10 [n=5, S310F/Y; n=3, V777L; n=1, T733I; n=1, L755S]), cholangiocarcinoma (n=11 [n=4, S310F; n=2, V842I; n=2, R678Q; n=1, V777L; n=1, V695E; n=1, D769Y]) and ampullary cancer (n=4 [n=1, S310F; n=1, G776C+H878Y; n=1, S310F+V777L; n=1, L755S]) demonstrated an overall response rate of 16.0% (95% CI=4.5-36.1) (PMID: 36746967). In the gallbladder cancer cohort, the median progression-free survival (PFS) was 3.7 months (95% CI=0.8-6.4), the median overall survival (OS) was 9.8 months (95% CI=2.4-NE), three patients achieved partial responses (PR) (S310F, V777L) and four patients demonstrated stable disease (SD) (T733I, L755S, S310Y) (PMID: 36746967). In the cholangiocarcinoma cohort, the median PFS was 1.4 months (95% CI=0.5-9.1), the median OS was 5.4 months (95% CI=0.8-16.2), two patients achieved PR (V659E, V777L) and two patients demonstrated SD (S310F, D769Y) (PMID: 36746967). In the ampullary cancer cohort, the median PFS was 1.1 months (95% CI=1.1-3.8), the median OS was 5.0 months (95% CI=3.7-10.2) and one patient demonstrated SD (G77C+H878Y) (PMID: 36746967)."
['Oncogenic Mutations'],"[{'ncitCode': 'C49094', 'drugName': 'Neratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 393, 'code': 'BILIARY_TRACT', 'color': 'Green', 'name': 'Biliary Tract', 'mainType': {'id': None, 'name': 'Biliary Tract Cancer, NOS', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'TISSUE', 'level': 1, 'tumorForm': 'SOLID'}",[],['36746967'],[],"Neratinib is an orally available, small-molecule pan-HER inhibitor that is FDA-approved as an extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. There are anecdotal clinical data to support the use of neratinib in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II SUMMIT (NCT01953926) trial of neratinib in patients with ERBB2 mutant solid tumors, patients with gallbladder cancer (n=10 [n=5, S310F/Y; n=3, V777L; n=1, T733I; n=1, L755S]), cholangiocarcinoma (n=11 [n=4, S310F; n=2, V842I; n=2, R678Q; n=1, V777L; n=1, V695E; n=1, D769Y]) and ampullary cancer (n=4 [n=1, S310F; n=1, G776C+H878Y; n=1, S310F+V777L; n=1, L755S]) demonstrated an overall response rate of 16.0% (95% CI=4.5-36.1) (PMID: 36746967). In the gallbladder cancer cohort, the median progression-free survival (PFS) was 3.7 months (95% CI=0.8-6.4), the median overall survival (OS) was 9.8 months (95% CI=2.4-NE), three patients achieved partial responses (PR) (S310F, V777L) and four patients demonstrated stable disease (SD) (T733I, L755S, S310Y) (PMID: 36746967). In the cholangiocarcinoma cohort, the median PFS was 1.4 months (95% CI=0.5-9.1), the median OS was 5.4 months (95% CI=0.8-16.2), two patients achieved PR (V659E, V777L) and two patients demonstrated SD (S310F, D769Y) (PMID: 36746967). In the ampullary cancer cohort, the median PFS was 1.1 months (95% CI=1.1-3.8), the median OS was 5.0 months (95% CI=3.7-10.2) and one patient demonstrated SD (G77C+H878Y) (PMID: 36746967)."
['Oncogenic Mutations'],"[{'ncitCode': 'C128799', 'drugName': 'Trastuzumab Deruxtecan'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 897, 'code': '', 'color': 'MIXED', 'name': '', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'MIXED', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38710187'],[],"Trastuzumab deruxtecan is an intravenously administered, HER2-targeted antibody that is FDA-approved for patients with unresectable or metastatic HER2-positive breast cancer previously treated with anti-HER2-based regimens in the metastatic setting. There are anecdotal clinical data to support the use of trastuzumab deruxtecan in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II DESTINY-PanTumor01 (NCT04639219) trial of trastuzumab deruxtecan in patients with ERBB2 mutant solid tumors, the biliary tract cancer cohort (n=19) demonstrated an overall response rate (ORR) of 10.5% (n=2) (95% CI=5.7-43.7) (PMID: 38710187)."
['Oncogenic Mutations'],"[{'ncitCode': 'C128799', 'drugName': 'Trastuzumab Deruxtecan'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 393, 'code': 'BILIARY_TRACT', 'color': 'Green', 'name': 'Biliary Tract', 'mainType': {'id': None, 'name': 'Biliary Tract Cancer, NOS', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'TISSUE', 'level': 1, 'tumorForm': 'SOLID'}",[],['38710187'],[],"Trastuzumab deruxtecan is an intravenously administered, HER2-targeted antibody that is FDA-approved for patients with unresectable or metastatic HER2-positive breast cancer previously treated with anti-HER2-based regimens in the metastatic setting. There are anecdotal clinical data to support the use of trastuzumab deruxtecan in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II DESTINY-PanTumor01 (NCT04639219) trial of trastuzumab deruxtecan in patients with ERBB2 mutant solid tumors, the biliary tract cancer cohort (n=19) demonstrated an overall response rate (ORR) of 10.5% (n=2) (95% CI=5.7-43.7) (PMID: 38710187)."
['Oncogenic Mutations'],"[{'ncitCode': 'C38692', 'drugName': 'Pertuzumab'}, {'ncitCode': 'C1647', 'drugName': 'Trastuzumab'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 897, 'code': '', 'color': 'MIXED', 'name': '', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'MIXED', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38748939'],[],"Pertuzumab and trastuzumab are intravenously administered, humanized monoclonal HER2-targeted antibodies that are NCCN-compendium listed in combination for the treatment of patients with HER2-positive biliary tract cancers. There are anecdotal clinical data to support the combined use of pertuzumab and trastuzumab in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II TAPUR (NCT02693535) trial of pertuzumab plus trastuzumab in seven patients with ERBB2 mutant biliary tract cancer (n=4, S310F; n=1, S310Y; n=1, R678Q; n=1, G776V), two patients achieved partial response (S310Y, S310F) (PMID: 38748939)."
['Oncogenic Mutations'],"[{'ncitCode': 'C38692', 'drugName': 'Pertuzumab'}, {'ncitCode': 'C1647', 'drugName': 'Trastuzumab'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 393, 'code': 'BILIARY_TRACT', 'color': 'Green', 'name': 'Biliary Tract', 'mainType': {'id': None, 'name': 'Biliary Tract Cancer, NOS', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'TISSUE', 'level': 1, 'tumorForm': 'SOLID'}",[],['38748939'],[],"Pertuzumab and trastuzumab are intravenously administered, humanized monoclonal HER2-targeted antibodies that are NCCN-compendium listed in combination for the treatment of patients with HER2-positive biliary tract cancers. There are anecdotal clinical data to support the combined use of pertuzumab and trastuzumab in patients with ERBB2 mutant biliary tract cancer. 
In the Phase II TAPUR (NCT02693535) trial of pertuzumab plus trastuzumab in seven patients with ERBB2 mutant biliary tract cancer (n=4, S310F; n=1, S310Y; n=1, R678Q; n=1, G776V), two patients achieved partial response (S310Y, S310F) (PMID: 38748939)."
